The US Food and Drug Administration has delayed its review of Novo Nordisk's hemophilia A drug denecimig, also known as Frehemgo, due to ongoing remediation activities at an unnamed manufacturing facility. The FDA did not raise safety or efficacy concerns regarding the drug's clinical data. While the delay pushes the expected US launch to the first half of 2027, Novo Nordisk's 2026 financial outlook remains unaffected as the company works to address the regulatory requests.
FDA review extension and timeline
- ▪The US Food and Drug Administration has not communicated a new timeline for its regulatory decision on Novo Nordisk's denecimig.
- ▪The US Food and Drug Administration extended its review of Novo Nordisk's Biologics License Application for the hemophilia A drug denecimig, also known as Frehemgo.
- ▪Novo Nordisk originally submitted the Biologics License Application for denecimig in September 2025, with an expected regulatory decision in the third quarter of 2026.
Manufacturing facility issues and remediation
- ▪The US Food and Drug Administration's review extension for denecimig was caused by ongoing facility remediation activities at an unnamed manufacturing site following a pre-license inspection.
- ▪The manufacturing facility issues prompting the US Food and Drug Administration's review delay do not impact any of Novo Nordisk's other marketed products.
- ▪Novo Nordisk is actively working to address the US Food and Drug Administration's requests for facility remediations as efficiently as possible.
Clinical efficacy and safety data
- ▪The US Food and Drug Administration did not identify any deficiencies related to the clinical efficacy or safety data of denecimig submitted in the Biologics License Application.
- ▪The Biologics License Application for denecimig is supported by the FRONTIER clinical trial programme, which evaluates the drug as a prophylactic treatment to prevent bleeding episodes in hemophilia A patients.
Global regulatory Status and launch plans
- ▪Pending regulatory approval, Novo Nordisk aims to launch denecimig in the United States in the first half of 2027.
- ▪Novo Nordisk plans to launch denecimig in Europe before the end of 2026, with a broader rollout across the European Union scheduled for 2027.
- ▪Denecimig received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use on September 17, 2026, and has secured approval in Saudi Arabia.
Market competition and catalysts
- ▪BMO Capital Markets analysts listed the regulatory decision for denecimig as one of seven key catalysts for Novo Nordisk, categorizing it as of medium importance.
- ▪Novo Nordisk's denecimig will compete directly with Roche's hemophilia treatment Hemlibra, which generated sales of roughly $5.8 billion in 2025.
Financial and strategic focus
- ▪Novo Nordisk has recently focused heavily on its diabetes and obesity franchises, namely through its popular semaglutide-based franchise of GLP-1s.
- ▪The extended US Food and Drug Administration review timeline for denecimig has no impact on Novo Nordisk's financial outlook for 2026.
Bloomington facility challenges
- ▪In 2026, quality problems at the Bloomington facility prompted Scholar Rock to drop the plant from its FDA approval application for the spinal muscular atrophy drug apitegromab.
- ▪Novo Nordisk has faced separate regulatory challenges at its Bloomington, Indiana fill-finish facility, which was acquired from Catalent in late 2024 and received an Official Action Indicated classification from the FDA.
Debatable claims
- ▪The FDA's delay of denecimig is a major setback for US hemophilia A patients
- ▪The FDA is justified in delaying drug approvals solely over manufacturing facility issues
Story comments
Loading comments…